Ultragenyx Pharmaceutical Inc. logo

RARE

Ultragenyx Pharmaceutical Inc.

$53.66

Earnings Summary

Revenue
$127.39Mn
Net Profits
$-123.19Mn
Net Profit Margins
-96.7%

Highlights

Revenue:

Ultragenyx Pharmaceutical Inc.’s revenue jumped 23.27% since last year same period to $127.39Mn in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 29.92% jump in its revenue since last 3-months.

Net Profits:

Ultragenyx Pharmaceutical Inc.’s net profit jumped 18.86% since last year same period to $-123.19Mn in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 22.84% jump in its net profits since last 3-months.

Net Profit Margins:

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 34.18% since last year same period to -96.7% in the Q4 2023. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 40.61% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ultragenyx Pharmaceutical Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-1.76
EPS Estimate Current Year
-1.76

Highlights

EPS Estimate Current Quarter:

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.76 - a -8.64% fall from last quarter’s estimates.

EPS Estimate Current Year:

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.76.

Key Ratios

Key ratios of the Ultragenyx Pharmaceutical Inc. post its Q4 2023 earnings

Earning Per Share (EPS)
-1.52
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-1.93

Highlights

Earning Per Share (EPS):

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 29.63% since last year same period to -1.52 in the Q4 2023. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 29.63% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc.’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc.’s return on equity (ROE) stands at -1.93.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-02-21
-1.62
-1.52
6.17%
2023-08-04
-2.07
-2.25
-8.7%
2023-05-05
-1.98
-2.33
-17.68%
2023-11-03
-2.08
-2.23
-7.21%